Rationing Medications During Shortages: How Ethical Decisions Are Made

When a life-saving drug runs out, who gets it? This isn’t a hypothetical question-it’s happening right now in hospitals across the U.S. In 2023, the FDA recorded 319 active drug shortages, with critical cancer drugs like carboplatin and cisplatin in short supply for months. Oncologists faced impossible choices: give a dose to one patient with stage IV ovarian cancer, or another with the same prognosis. No one wants to play God. But when supply breaks down, someone has to decide-and those decisions need to be ethical, not random.

Why Medication Rationing Is Happening Now

Drug shortages aren’t new, but they’ve gotten worse. In 2005, there were 61 shortages. By 2011, that number jumped to 251. Today, it’s over 300. The main culprits? A fragile supply chain, too few manufacturers, and reliance on overseas production. Just three companies make 85% of generic injectable drugs in the U.S. When one factory shuts down for quality issues, entire drug classes vanish overnight. Sterile injectables-like chemo drugs, antibiotics, and anesthetics-are the most vulnerable. They’re hard to make, hard to store, and hard to replace.

The Ethical Frameworks That Guide Decisions

Ethical rationing isn’t about guessing or flipping a coin. It’s built on clear, evidence-based principles. The most widely accepted model comes from Daniels and Sabin’s "accountability for reasonableness" framework. It requires four things: publicity (everyone knows how decisions are made), relevance (criteria must be grounded in medical evidence), appeals (patients or families can challenge a decision), and enforcement (someone makes sure rules are followed).

The American Society of Clinical Oncology (ASCO) added cancer-specific rules in 2023. Their guidance says allocation should happen at the committee level-not at the bedside. A team of pharmacists, oncologists, nurses, ethicists, and even patient advocates should review cases. This isn’t bureaucracy-it’s fairness. Bedside decisions, made under pressure, lead to bias, inconsistency, and burnout.

Five core criteria are used to rank patients:

• Urgency of need-Who will die without this drug?
• likelihood of benefit-Is there a real chance this treatment will work?
• duration of benefit-Will it extend life for weeks, months, or years?
• Saving the most years of life-Prioritizing younger patients with longer life expectancy
• Instrumental value-Do they serve a critical function (e.g., frontline healthcare workers)?

What Happens When There’s No System?

In many hospitals, there’s no formal process. A 2022 study in JAMA Internal Medicine found that over half (51.8%) of rationing decisions were made by individual clinicians alone. That’s not ethics-it’s survival mode. Nurses and doctors are left to choose between patients with no guidance. The result? Higher burnout, moral distress, and deep inequities.

One oncologist shared on ASCO’s forum: "I’ve had to choose between two stage IV ovarian cancer patients for limited carboplatin doses three times this month with no institutional guidance." That’s not a rare story. Only 4.9% of hospital committees include ethicists. Only 13.3% include physicians. That’s not a team-it’s a gap.

Rural hospitals are hit hardest. Sixty-eight percent have no formal rationing protocol. Urban academic centers? Only 32% lack one. That means a patient in Nebraska might get a lifesaving drug because their hospital has a committee, while someone in a nearby town gets nothing. The system isn’t broken-it’s uneven.

How Hospitals Are Trying to Fix This

Some places are doing better. The Minnesota Department of Health released a detailed plan in April 2023 for carboplatin and cisplatin shortages. It ranked patients into tiers:

• Tier 1: Curative intent, no alternative therapy available
• Tier 2: Palliative intent, but treatment significantly improves quality of life
• Tier 3: Alternative therapies exist

Hospitals with formal committees report 41% lower clinician distress scores. They also document every decision in the electronic health record-why a patient was prioritized, how they were informed, whether they appealed. Only 22% of hospitals do this consistently.

The CDC and ASCO now offer free tools: decision support templates, ethics training modules, and communication scripts for talking to patients. ASCO’s online tool, launched in May 2023, walks clinicians through each step. It’s not perfect-but it’s a start.

The Hidden Cost: Patients Who Never Know

One of the most disturbing facts? Only 36% of patients are told their treatment is being rationed. Families are left wondering why a drug was suddenly stopped. Some assume it’s a mistake. Others think their doctor gave up. A 2021 study by the Patient Advocate Foundation documented 127 formal complaints about undisclosed rationing. That’s not just poor communication-it’s a betrayal of trust.

Ethical rationing demands transparency. If a patient doesn’t know they’re on a waiting list, they can’t ask questions. They can’t appeal. They can’t prepare. And that’s not just unethical-it’s cruel.

What’s Next? The Fight for Fairness

The FDA is working on an AI-powered early warning system to predict shortages before they happen. The National Academy of Medicine is developing standardized metrics for allocation by mid-2024. And in January 2024, 15 states launched pilot programs to certify hospital rationing committees-finally giving them formal authority and training.

But progress is slow. Manufacturers still don’t meet notification requirements. Group purchasing organizations prioritize cost over reliability. And hospitals? Many still don’t have the staff, time, or funding to build proper systems.

The bottom line: rationing isn’t about scarcity. It’s about choice. And when we don’t choose wisely, we choose injustice.